Funded Sarcoma Research Projects

Research That

Makes a Difference

Rein in Sarcoma funds research which directly contributes to a broader understanding of sarcoma, supports new treatment strategies, and helps improve outcomes for patients of all ages. The projects we support are chosen for their potential to make meaningful clinical impact and to expand knowledge in areas where progress is most needed.

Each funded project represents the dedication of scientists, clinicians, and patient advocates working together to bring new possibilities to the sarcoma community.

Rein in Sarcoma’s Funded Projects

Click to learn about the research we have funded at top research institutions such as the University of Minnesota, Mayo Clinic, Children’s Hospitals, and Clinics of Minnesota.

2025 1 project · $5,000

Project Title

Principal Investigator

Institution

Amount

LMS SPORE

Dr. Baker & Team

SARC

$5,000

Project Title

Principal Investigator

Institution

Amount

LMS SPORE

Dr. Baker & Team

SARC

$5,000

University of Calgary – Biology, mechanisms, and targetability of cancer-associated fibroblasts in rhabdomyosarcoma

Aru Narendran MD, PhD. FAAP

University of Calgary

$55,000

University of Minnesota – Unraveling the Mechanisms of Immune Evasion in CIC::DUX4 Sarcoma

Dr. Darko Boshnakovski

University of Minnesota

$50,000

Aveni Foundation – DeltaRex-G Manufacture in Memory of Yunhui Chae-Banks

Dr. Erlina Gordon

Aveni Foundation

$76,665.56

Project Title

Principal Investigator

Institution

Amount

Targeting the Cell Cycle and Autophagy Reciprocal Communication Pathways in Sarcomas

Dr. Erin Dickerson

University of Minnesota

$50,000

Clarifying the Molecular Profile of DICER1-related sarcomas

Dr. Kris Ann Schultz

Children’s Minnesota

$15,000

Sarcoma Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography

Matthew T. Houdek, MD & Mikaela H. Sullivan, MD

Mayo Clinic

$25,000

LMS SPORE

Dr. Baker & Team

SARC

$5,000

Project Title

Principal Investigator

Institution

Amount

Identification of new strategies to therapeutically intervene for rhabdomyosarcomas

Berkley E. Gryder, PhD

Case Western Reserve University

$54,000

Characterization of Ewing Sarcoma patient-derived induced pluripotent stem cells

Beau Webber, PhD

University of Minnesota

$50,000

Project Title

Principal Investigator

Institution

Amount

Identifying and Characterizing the Cells that Create the Primary and Metastatic Sarcoma Niche

Jaime Modiano

UMN

$50,000

DICER1-related sarcomas

Kris Ann Schultz Damon Olson

Childrens

$20,000

Clinical and laboratory tools to evaluate treatment tolerability in older patients with soft tissue sarcoma

Thanh Ho

Mayo Clinic

$20,000

Project Title

Principal Investigator

Institution

Amount

eBAT as a Modulator of the Myeloid Immune Checkpoint in Cancer

Dr. Jaime Modiano

UMN

$50,000

Using Propranolol to Generate an Anti-Tumor Microenvironment

Dr. Erin Dickerson

UMN

$50,000

Computationally Deciphering the Paths of Genomic Catastropohe in Osteosarcoma

Dr. Ruping Sun

UMN

$50,000

DICER1-related Genitourinary Sarcomas

Dr. Kris Ann P. Schultz

Children’s Minnesota

$15,000

Targeting the Immune Checkpoint B7-H3 for the Treatment of Rhabdomyosarcoma.

Dr. Fabrice Lucien-Matteoni

Mayo Clinic

$25,000

Project Title

Principal Investigator

Institution

Amount

MYOG: Promoter-Controlled Oncolytic Adenovirus to Treat PAX3-FOXO1-Positive Rhabdomyosarcoma

Dr. Masato Yamamoto / Hideki Yoshida

UMN

$50,000

SHH signaling genetic alterations: A relevant and targetable trait in peripheral nerve sheath sarcomas

Dr. David Largaespada

UMN

$50,000

Registry-based analysis of risk and survival for young-onset sarcomas

Dr. Logan Spector

UMN

$50,000

2019 Integrated Proteomic and Transcriptomic Profiling of Rhabdomyosarcoma Reveals Target Antigens for Immune-Based Therapies

Dr. Patricio Gargollo

Mayo

$25,000

Expanding Opportunities For Early Detection of Sarcoma

Dr. Megan Hilgers and Dr. Kris Ann P. Schultz

Children’s Minnesota

$20,000

Project Title

Principal Investigator

Institution

Amount

Predicting relapse and response to chemotherapy in sarcoma

Dr. Amy Skubitz

UMN

$49,000

Retrospective and Prospective Comparison of Prognostic Transcriptional Biomarkers in Osteosarcoma using NanoString RNA profiling

Dr. Aaron Sarver / Dr. Edward Cheng

UMN

$49,000

Reprogramming cholesterol metabolism in sarcomas using adrenergic receptor antagonists

Dr. Erin Dickerson

UMN

$25,000

Identification of novel drivers of Ewing Sarcoma through engineered transformation of cells with differing levels of African admixture

Dr. Beau Weber

UMN

$25,000

Pilot Study of Circulating Cell Free Tumor DNA as a Biomarket in Sarcoma

Dr. Brittany Siontis / Dr. Steven Robinson

Mayo

$30,000

Identifying Gene Fusions in Pleuropulmonary Blastoma

Dr. Kris Ann Schultz

Children’s Minnesota

$15,000

Project Title

Principal Investigator

Institution

Amount

Engaging the Immune system as a strategy for sarcoma therapy

Dr. Antonella Borgatti

UMN

$40,000

Effects of beta-adrenergic receptor antagonists on sarcoma radiosensitivity

Dr. Jessica Lawrence

UMN

$35,000

Enhancement of the Response of Sarcoma to SBRT by Targeting HIF-1a

Dr. L. Chinsoo Cho

UMN

$25,000

Defining the Immunologic Landscape of Spontaneous Canine Osteosarcoma

Dr. Jaime Modiano

UMN

$25,000

Targeting Autophagy as a Therapeutic Strategy in Osteosarcoma

Dr. Avudaiappan Maran

Mayo Clinic

$25,000

Identifying Blood-Based Biomarkers to Improve Outcome in Pleuropulmonary Blastoma

Dr. Kris Ann Schultz

Children’s Minnesota

$15,000

In Support of the SARC Specialized program in Research Excellence (SPORE) application

Laurence Baker

SARC

$ 5,000

Project Title

Principal Investigator

Institution

Amount

The impact of Beta Adrenergic receptors

Dr. Erin Dickerson

UMN

$50,000

A better process for predicting GIST reoccurrence and other soft tissue sarcomas

Dr. Amy Skubitz

UMN

$23,000

Improving the survival rate of Osteosarcoma patients

Dr. Subbaya Subramanian

UMN

$49,450

Project Title

Principal Investigator

Institution

Amount

The use of FDG-PET CT metabolic response to increase the therapeutic ratio of treatment for high grade, large soft tissue sarcomas

Dr. Edward Cheng

UMN

$29,000

The Role of ATRX and ALT in sarcoma

Eric Hendrickson

UMN

$24,000

Mechanism-Based Expansion of the Tumor Repertoire for an Effective Sarcoma Therapy

Dr. Jaime Modiano

UMN

$24,000

The Role of NFIB in Metastatic Pediatric Osteosarcoma

Dr. Branden Moriarity

UMN

$24,000

Enhancement of the response of sarcoma to SBRT

Dr. Kathryn Dusenbery

UMN

$24,000

Project Title

Principal Investigator

Institution

Amount

Targeting Semaphorin-4D for Osteosarcoma Therapy

Dr. David Largaespada

UMN

$40,000

MicroRNAs in the Progression of Osteosarcoma

Dr. Subbaya Subramanian

UMN

$35,000

Correlation of Macrophage Infiltration and Microvessel Density to Clinical Outcome in Sarcoma Patients

Dr. Amy Skubitz

$30,000

Project Title

Principal Investigator

Institution

Amount

Preclinical evaluation of Minnelide in the treatment of osteosacoma

Dr. Subbaya Subramanian

UMN

$40,000

Quantification of macrophage infiltration and microvessel density

Dr. Amy Skubitz

UMN

$40,000

Treatment of sarcoma with metformin in combination with radiotherapy

Dr. Chang Song

UMN

$20,000

Targeting Semaphorin-4D for Osteosarcoma Therapy

Dr. David Largaespada

UMN

$40,000

MicroRNAs in the Progression of Osteosarcoma

Dr. Subbaya Subramanian

UMN

$35,000

Correlation of Macrophage Infiltration and Microvessel Density to Clinical Outcome in Sarcoma Patients

Dr. Amy Skubitz

$30,000

Project Title

Principal Investigator

Institution

Amount

Tunneling Nanotubes as Novel targets in Osteosarcoma

Dr. Emil Lou

UMN

$5,310

Treatment of sarcoma with metformin in combination with radiotherapy

Dr. Chang Song

UMN

$30,640

Functional Analysis of Low Copy Number Gain of Human 8q24 in Osteosarcoma

Anindya Bagchi

UMN

$24,460

The role of tumor cell multipotency and the microenvironment as determinants in sarcoma development and progression

Dr. Erin Dickerson

UMN

$33,230

Isolation of human osteoblasts for functional evaluation of osteosarcoma susceptibility alleles

Dr. Logan Spector

UMN

$23,130

Identification of Potential Therapeutic Targets for Sarcomas

Dr. Amy Skubitz

UMN

$33,230

Project Title

Principal Investigator

Institution

Amount

Significance of Rb inactivation in clinical behavior of osteosarcoma

Dr. Jaime Modiano

UMN

$49,918

T-cell Targeting of Sarcomas

Dr. Xianzheng Zhou

UMN

$50,000

Allogeneic, Haploidentical NK cell Infusions for High Sarcoma Patients

Michael Verneris

UMN

$48,300

Quantification of four biomarkers that demonstrate clinical correlations in aggressive fibromatosis

Dr. Amy Skubitz

UMN

$21,366

Translational Award-Complete Genome Sequencing and Analysis of Human osteosarcoma

Dr. Subbaya Subramanian

UMN

$25,000

Translational Award-Exploring intratumoral genetic heterogeneity in rhabdomyosarcoma and osteosarcoma

Dr. David Largaespada

UMN

$25,000

Project Title

Principal Investigator

Institution

Amount

Characterization of sarcoma stem cells and their role in chemoresistance and relapse

Dr. Amy Skubitz

UMN

$45,000

Establishment of a miRNA Serum Biomakers in Well and De-differenciated liposarcomas

Dr. Christian Ogilvie

UMN

$36,900

Fibroblast Growth Factor Receptors as Gtargets for Rhabdomyosarcoma Therapy

Dr. David Largaespada

UMN

$42,902

Patient Education video series: Amputation in pediatric sarcoma patients

Dr. Edward Cheng

UMN

$18,000

2010-2011 RIS Sarcoma Scholarship Award

Dr. Kathryn Dusenbery

UMN

$4,000

Project Title

Principal Investigator

Institution

Amount

Clinical Correlations Associated with Genes Upregulated in Fibromatosis

Dr. Amy Skubitz

UMN

$34,500

MicroRNA Regulatory Networks in Synovial Sarcoma

Dr. Subbaya Subramanian

UMN

$34,500

Scholarship for a 2nd or 3rd year medical student with an interest in cancer and cancer education

Dr. Kathryn Dusenbery

UMN

$1,000

Therapeutic implications of P13K inhibition of E2F1 apoptotic function in osteosaracoma

Dr. Timothy Hallstrom

UMN

$24,000

Somatic mutations in Nijmegen Breakage Syndrome Gene (NBS1) in Rhabdomyosarcomas

Dr. Simona Ognjanovic

UMN

$16,000

Evaluation of PET as a Predictor of Response to Preoperative Treatment for Soft Tissue Sarcoma, a Phase II Trial

Dr. Edward Cheng

UMN

$20,000

Project Title

Principal Investigator

Institution

Amount

Heritable Influence on VEGF Receptor Function in a Canine Endothelial STS

Dr. Jaime Modiano

UMN

$20,850

The role of p53 mutations in pediatric alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcona (ERMS)

Dr. Simona Ognjanovic

UMN

$36,936

MicroRNA Expression Profile of Synovial Sarcoma

Dr. Subbaya Subramanian

UMN

$39,020

Patient education video series: amputation, rotationplasty and limb salvage

Dr. Edward Cheng

UMN

$7,200

Current Funding

Programs

Since 2001, Rein in Sarcoma has invested more than $3 million in research and education, supporting leading institutions committed to improving sarcoma diagnosis, treatment, and patient care.

University of Minnesota

Rein in Sarcoma supports research at the University of Minnesota that aims to improve sarcoma diagnosis, treatment, and long-term outcomes for patients of all ages.

Mayo Clinic

Our funding helps Mayo Clinic investigators advance innovative approaches to sarcoma care through clinical research and scientific discovery.

University of Calgary

Through the Kasey Altman Research Fund, Rein in Sarcoma contributes to groundbreaking studies at the University of Calgary that explore new ways to understand and treat rare sarcoma subtypes.

Children’s Hospital and Clinics of Minnesota

We partner with Children’s Minnesota to support research focused on improving treatment and survivorship for children and adolescents facing sarcoma.

SARC and other international collaborations

We proudly support SARC and global research partners working together to accelerate progress and bring new hope to sarcoma patients worldwide.

minnesota

University of Minnesota

Rein in Sarcoma supports research at the University of Minnesota that aims to improve sarcoma diagnosis, treatment, and long-term outcomes for patients of all ages.

Mayo-Clinic-Logo

Mayo Clinic

Our funding helps Mayo Clinic investigators advance innovative approaches to sarcoma care through clinical research and scientific discovery.

images (1)

University of Calgary

Through the Kasey Altman Research Fund, Rein in Sarcoma contributes to groundbreaking studies at the University of Calgary that explore new ways to understand and treat rare sarcoma subtypes.

images

Children’s Hospital and Clinics of Minnesota

We partner with Children’s Minnesota to support research focused on improving treatment and survivorship for children and adolescents facing sarcoma.

sarctrials_logo

SARC and other international collaborations

We proudly support SARC and global research partners working together to accelerate progress and bring new hope to sarcoma patients worldwide.

Awards-Charity Navigator

SARC and other international collaborations

Item description – lobortis ac odio fringilla laoreet. Morbi hendrerit in massa eget ullamcorper. Donec nec sapien orci.

Donor Recognition

Every funded project is made possible through the generosity of donors, foundations, and community partners who believe in progress and hope. We are proud to recognize their support and share the impact their contributions have on research and patient care.

Annual Reports: Transparent updates that show how funds are allocated and the outcomes they help achieve.

Donor Spotlights: Stories that celebrate the individuals and organizations whose generosity fuels discovery.

Impact Stories: Real examples of how funding supports research and improves care for patients and families.

Current and Past Projects

Our funded projects highlight the tangible outcomes of donor support and research collaboration. Each initiative reflects our commitment to transparency, innovation, and patient-centered progress.

Research Grants: Supporting cutting-edge sarcoma studies at leading institutions.

Patient Support Programs: Expanding resources and guidebooks for newly diagnosed patients and families.

Educational Initiatives: Funding training modules, symposia, and awareness campaigns to improve early diagnosis and treatment.

Apply For Funding

Rein in Sarcoma welcomes researchers and institutions dedicated to advancing knowledge and improving care for people affected by sarcoma. Our funding opportunities are designed to support innovative ideas and meaningful research that have the potential to shape the future of sarcoma treatment.

Grant Applications: Access guidelines and submission details for current and upcoming funding opportunities.

Eligibility Criteria: Learn more about who is eligible to apply and how institutions and researchers can qualify for support.

Collaboration Opportunities: Partner with Rein in Sarcoma to strengthen your research, expand its reach, and increase its impact 

Partnering For Progress

By funding projects that bring together researchers, healthcare providers, and the sarcoma community, Rein in Sarcoma ensures that every investment moves us closer to meaningful breakthroughs. Together, we are building a future defined by innovation, collaboration, and hope for those affected by sarcoma.